The ACVR1B Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal cell population derived from the A-549 human lung adenocarcinoma cell line, in which the ACVR1B gene has been disrupted. This knockout model provides a powerful tool for dissecting activin and TGF-?? signaling pathways. The polyclonal nature ensures representation of diverse editing events, enabling robust analysis of gene function without clonal selection artifacts. Generated via CRISPR/Cas9-mediated gene disruption, the cells allow researchers to interrogate the loss-of-function consequences of ACVR1B in a relevant epithelial context.
The A-549 host cell line is a widely employed model of alveolar epithelial cells, originally established from a human lung adenocarcinoma. These adherent epithelial cells exhibit characteristics suitable for studying lung cancer biology, epithelial-to-mesenchymal transition (EMT), and responses to extracellular stimuli. Their genetic background and well-characterized signaling responses make them a standard platform for investigating oncogenic pathways and therapeutic vulnerabilities in non-small cell lung cancer and other epithelial malignancies.
ACVR1B encodes a type I serine/threonine kinase receptor that functions as an essential mediator of activin and TGF-?? superfamily signaling. Upon ligand binding (e.g., Activin A, Activin B, Nodal, Myostatin), ACVR1B is recruited and phosphorylated by type II receptors ACVR2A or ACVR2B, leading to the recruitment and activation of SMAD2 and SMAD3 via phosphorylation. Activated SMAD2/3 form complexes with the co-mediator SMAD4 and translocate to the nucleus to transcriptionally regulate target genes such as SNAI1, CDKN1A, and PAI-1. Beyond the canonical SMAD pathway, ACVR1B also activates non-SMAD signaling including the MAP kinases ERK, p38, and JNK. The receptor is subject to modulation by interacting factors including BAMBI, SMAD7, Cripto, SARA, and FKBP12, which fine-tune signal transduction.
In the A-549 cellular context, ACVR1B-dependent signaling governs critical processes such as cell proliferation, differentiation, apoptosis, and migration. Disruption of ACVR1B in this lung adenocarcinoma model abrogates activin/TGF-??-mediated cellular responses, providing a clean background to assign function to this receptor. The knockout therefore enables precise dissection of ACVR1B??s role in EMT, a key step in cancer metastasis, and in the regulation of genes controlling cell cycle arrest and extracellular matrix remodeling. This model is particularly valuable for distinguishing ACVR1B-specific effects from those mediated by other TGF-?? family receptors.
Researchers can employ this knockout model in a wide array of experimental contexts, including phospho-signaling analysis via Western blotting for phospho-SMAD2/3, RT-qPCR quantification of downstream targets such as SNAI1 and CDKN1A, and functional assays like Transwell migration and proliferation assays. Furthermore, the polyclonal pool is suitable for genome-wide expression profiling by RNA-seq and high-content signaling studies. This ACVR1B knockout model serves as a robust platform for drug sensitivity screening and target validation in TGF-??-related cancers. For further technical information or ordering, please contact Ascent Research.
